Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance

被引:8
作者
Baldursdottir, Theodora Run [1 ]
Love, Thorvardur Jon [1 ,2 ]
Gislason, Gauti Kjartan [2 ]
Bjorkholm, Magnus [3 ,4 ]
Mellqvist, Ulf-Henrik [5 ]
Lund, Sigrun Helga [2 ]
Blimark, Cecilie Hveding [6 ]
Turesson, Ingemar [7 ]
Hultcrantz, Malin [3 ,4 ,8 ]
Landgren, Ola [9 ]
Kristinsson, Sigurdur Yngvi [1 ,2 ]
机构
[1] Natl Univ Hosp Reykjavik, Landspitali, Reykjavik, Iceland
[2] Univ Iceland, Fac Med, Sturlugata 8, IS-101 Reykjavik, Iceland
[3] Karolinska Univ Hosp, Dept Med, Div Hematol, Stockholm, Sweden
[4] Karolinska Inst, Stockholm, Sweden
[5] South Elvsborg Hosp, Hematol, Boras, Sweden
[6] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden
[7] Skane Univ Hosp, Malmo, Sweden
[8] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Program, Miami, FL USA
基金
欧盟地平线“2020”;
关键词
autoimmune disease; lymphoproliferative; monoclonal gammopathy of undetermined significance; multiple myeloma; population‐ based; PRECEDES MULTIPLE-MYELOMA; SIGNIFICANCE MGUS; HODGKIN-LYMPHOMA; LONG-TERM; FOLLOW-UP; PREVALENCE; DISORDERS; MALIGNANCIES; HISTORY;
D O I
10.1111/ejh.13563
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives and methods We conducted a population-based study including 19 303 individuals diagnosed with MGUS in Sweden from 1985 to 2013, with the aim to determine whether a prior history of autoimmune disease, a well-described risk factor for MGUS is a risk factor for progression of MGUS to multiple myeloma (MM) or lymphoproliferative diseases (LPs). Using the nationwide Swedish Patient registry, we identified MGUS cases with versus without an autoimmune disease present at the time of MGUS diagnosis and estimated their risk of progression. Results A total of 5612 (29.1%) MGUS cases had preceding autoimmune diseases. Using Cox proportional hazards models, we found the risk of progression from MGUS to MM (HR = 0.83, 95% CI 0.73-0.94) and LPs (HR = 0.84, 95% CI 0.75-0.94) to be significantly lower in MGUS cases with prior autoimmune disease (compared to MGUS cases without). Conclusions In this large population-based study, a history of autoimmune disease was associated with a reduced risk of progression from MGUS to MM/other LPs. Potential underlying reason is that MGUS caused by chronic antigen stimulation is biologically less likely to undergo the genetic events that trigger progression. Our results may have implications in clinical counseling for patients with MGUS and underlying autoimmune disease.
引用
收藏
页码:380 / 388
页数:9
相关论文
共 30 条
  • [21] Nilsson A C, 1994, Lakartidningen, V91, P603
  • [22] Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
    Perez-Persona, Ernesto
    Mateo, Gema
    Garcia-Sanz, Ramon
    Mateos, Maria-Victoria
    de las Heras, Natalia
    Garcia de Coca, Alfonso
    Hernandez, Jose M.
    Galende, Josefina
    Martin-Nunez, Guillermo
    Barez, Abelardo
    Alonso, Jose M.
    Martin, Alejandro
    Lopez-Berges, Consuelo
    Orfao, Alberto
    San Miguel, Jesus F.
    Vidriales, Maria-Belen
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (01) : 110 - 114
  • [23] International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Palumbo, Antonio
    Blade, Joan
    Merlini, Giampaolo
    Mateos, Maria-Victoria
    Kumar, Shaji
    Hillengass, Jens
    Kastritis, Efstathios
    Richardson, Paul
    Landgren, Ola
    Paiva, Bruno
    Dispenzieri, Angela
    Weiss, Brendan
    Leleu, Xavier
    Zweegman, Sonja
    Lonial, Sagar
    Rosinol, Laura
    Zamagni, Elena
    Jagannath, Sundar
    Sezer, Orhan
    Kristinsson, Sigurdur Y.
    Caers, Jo
    Usmani, Saad Z.
    Lahuerta, Juan Jose
    Johnsen, Hans Erik
    Beksac, Meral
    Cavo, Michele
    Goldschmidt, Hartmut
    Terpos, Evangelos
    Kyle, Robert A.
    Anderson, Kenneth C.
    Durie, Brian G. M.
    San Miguel, Jesus F.
    [J]. LANCET ONCOLOGY, 2014, 15 (12) : E538 - E548
  • [24] Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
    Rajkumar, SV
    Kyle, RA
    Therneau, TM
    Melton, LJ
    Bradwell, AR
    Clark, RJ
    Larson, DR
    Plevak, MF
    Dispenzieri, A
    Katzmann, JA
    [J]. BLOOD, 2005, 106 (03) : 812 - 817
  • [25] Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
    Smedby, KE
    Hjalgrim, H
    Askling, J
    T Chang, E
    Gregersen, H
    Porwit-MacDonald, A
    Sundström, C
    Åkerman, M
    Melbye, M
    Glimelius, B
    Adami, HO
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (01): : 51 - 60
  • [26] Swedish National Board of Health, 2008, PAT
  • [27] Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003
    Turesson, Ingemar
    Linet, Martha S.
    Bjorkholm, Magnus
    Kristinsson, Sigurdur Y.
    Goldin, Lynn R.
    Caporaso, Neil E.
    Landgren, Ola
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (10) : 2260 - 2266
  • [28] Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden
    Turesson, Ingemar
    Kovalchik, Stephanie A.
    Pfeiffer, Ruth M.
    Kristinsson, Sigurdur Y.
    Goldin, Lynn R.
    Drayson, Mark T.
    Landgren, Ola
    [J]. BLOOD, 2014, 123 (03) : 338 - 345
  • [29] Prevalence of monoclonal gammopathy of undetermined significance in Thailand
    Watanaboonyongcharoen, Phandee
    Nakorn, Thanyaphong Na
    Rojnuckarin, Ponlapat
    Lawasut, Panisinee
    Intragumtornchai, Tanin
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (02) : 176 - 181
  • [30] A monoclonal gammopathy precedes multiple myeloma in most patients
    Weiss, Brendan M.
    Abadie, Jude
    Verma, Pramvir
    Howard, Robin S.
    Kuehl, W. Michael
    [J]. BLOOD, 2009, 113 (22) : 5418 - 5422